$0.93
0.62% yesterday
Nasdaq, Nov 28, 05:18 pm CET
ISIN
US79400X1072
Symbol
SLRX

Salarius Pharmaceuticals Inc Stock price

$0.93
-2.91 75.85% 1M
-10.63 92.00% 6M
-26.68 96.65% YTD
-21.88 95.94% 1Y
-242.68 99.62% 3Y
-2,054.08 99.96% 5Y
-923,999.08 100.00% 10Y
-1,121,249.08 100.00% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.04 4.79%
ISIN
US79400X1072
Symbol
SLRX
Industry

Key metrics

Basic
Market capitalization
$5.4m
Enterprise Value
$4.6m
Net debt
positive
Cash
$790.0k
Shares outstanding
140.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
50.0%
Return on Equity
-368.8%
ROCE
624.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-5.2m | -
EBIT
$-5.2m | $-6.2m
Net Income
$-5.1m | $-1.3m
Free Cash Flow
$-4.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
23.0% | -
EBIT
23.2% | -9.1%
Net Income
21.1% | 76.5%
Free Cash Flow
46.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-36.1
FCF per Share
$-29.6
Short interest
8.0%
Employees
2
Rev per Employee
$0.0
Show more

Is Salarius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Salarius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

Hold
50%
Sell
50%

Financial data from Salarius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.67 4.67
10% 10%
-
- Research and Development Expense 0.50 0.50
68% 68%
-
-5.18 -5.18
23% 23%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.18 -5.18
23% 23%
-
Net Profit -5.10 -5.10
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Salarius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Salarius Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
9 days ago
HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker “SLRX.
Neutral
GlobeNewsWire
15 days ago
Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP 3 ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering HOUSTON and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals (Nasdaq: SLRX) (“Salar...
Neutral
PRNewsWire
17 days ago
HOUSTON , Nov. 11, 2025 /PRNewswire/ -- Salarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses. The offering is comprised of 2,514,335 shares of its common stock ("Common Stock") and...
More Salarius Pharmaceuticals Inc News

Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Head office United States
CEO David Arthur
Employees 2
Founded 2014
Website salariuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today